Development of activated natural killer (NK) cells mediated immunotherapy in cancer

Research for the effect of biological response modifiers (BRMs) on natural killer (NK) cell cytotoxicity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN79498301

Enrollment

Registered

2008-08-08

Start date

2008-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunotherapy in cancer Cancer Malignant neoplasms of independent (primary) multiple sites

Interventions

A blood sample will be obtained from each participant. A variety of BRMs (small synthetic peptides, interleukins, natural extracts) will be tested on the blood samples to measure their effect on NK ce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers aged 18 years or older, both males and females 2. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Aged less than 18 years 2. Those who do not speak Korean

Design outcomes

Primary

Measure	Time frame
1. To find BRMs that lead to the highest levels of NK cell cytotoxicity in the treated blood samples 2. To find the optimum dose and duration of treatment with the BRMs found to elicit highest levels of NK cell cytotoxicity	—

Secondary

Measure	Time frame
Gene expression profiles associated with peripheral blood lymphocyte (PBL) cytotoxicity and related mechanisms in the blood samples.	—

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026